**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 79220

**Manuscript Type:** MINIREVIEWS

**Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection**

Wongtanasarasin W. Cholestatic liver injury during and after COVID-19

Wachira Wongtanasarasin

**Wachira Wongtanasarasin,** Department of Emergency Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

**Wachira Wongtanasarasin,** Department of Emergency Medicine, UC Davis School of Medicine, Sacramento, CA 95817, United States

**Author contributions:** Wongtanasarasin W designed the protocol, contributed to data collection, evaluation, and visualization, wrote the first draft of the manuscript, and critically reviewed the final version of the manuscript.

**Corresponding author: Wachira Wongtanasarasin, MD, Assistant Professor,** Department of Emergency Medicine, Faculty of Medicine, Chiang Mai University, 110 Intavarorot Street, Sriphum, Chiang Mai 50200, Thailand. wachir\_w@hotmail.com

**Received:** August 9, 2022

**Revised:** September 21, 2022

**Accepted:** October 19, 2022

**Published online:**

**Abstract**

The 2019 coronavirus disease (COVID-19), resulting from the severe acute respiratory syndrome 2 (SARS-CoV-2) virus, has transformed our globe and provided a new perspective on respiratory tract infections. However, COVID-19 would not be recognized as a condition restricted to only pneumonia. This narrative review was conducted by searching manuscripts in several databases, including PubMed/Medline, Web of Science, and Reference Citation Analysis, from December 2019 to July 2022. Many studies have revealed a broad spectrum of potential systemic symptoms, including biliary complications. Although biliary injury has been observed in a very low proportion of COVID-19 patients, it is associated with increased mortalities and long-term morbidities. We identify a cholangiopathy condition in individuals during infection and after recovering from severe COVID-19, defined by a significant increase in serum alkaline phosphatase and signs of bile duct injury. Understanding the pathogeneses behind this condition would help us develop new techniques to prevent these complications. This review thoroughly discusses and summarizes the current information regarding COVID-19-associated cholangiopathy. In addition, the possible explanations for COVID-19-associated cholangiopathy are presented. Since the exact pathogenesis may not be concluded, this review could provide relevant information to encourage additional investigations shortly.

**Key Words:** COVID-19; Cholestatic injury; Cholangiopathy; Alkaline phosphatase

Wongtanasarasin W. Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection. *World J Virol* 2022; In press

**Core Tip:** The 2019 coronavirus disease (COVID-19) is not only regarded as a respiratory tract disease but also demonstrates a wide range of systemic consequences, including the biliary tract. A significant increase in serum alkaline phosphatase and signs of biliary injury on imaging and/or pathology are the hallmarks of COVID-19-associated cholangiopathy. Direct viral invasion, ischemic injury related to microvascular coagulopathy, drug-induced cholestatic liver injury, alteration of the gut microbiota, and cytokine release syndrome are proposed as potential explanations for cholangiopathy associated with severe COVID-19 infection.

**INTRODUCTION**

Since December 2019, the recent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), later confirmed as the source of the 2019 coronavirus disease (COVID-19), has turned into a global threat to public health[1]. With a rapidly increasing number of overall cases, the World Health Organization announced the disease pandemic in March 2020. Currently, COVID-19 has caused about 577 million cases and over 6 million deaths worldwide[2].

SARS-CoV-2 is greatly transmitted by the droplet route[3], with respiratory symptoms (*i.e.*, sore throat, cough, and dyspnea) being the most prevalent manifestation as a result of host seeding *via* angiotensin-converting enzyme 2 (ACE-2) receptors present primarily in type II alveolar cells of the lungs[4,5]. Although respiratory and non-specific symptoms such as fever, myalgia, and fatigue represented the most common presentations in patients with COVID-19 infection, gastrointestinal and hepatic symptoms have also been observed[6,7]. Infected individuals reported nausea, vomiting, and abdominal discomfort[6,8,9]. Current evidence has proposed pneumonia as a severe COVID-19 feature[10]. However, complications are notably distinguishable, and the virus has impacted different organ systems[11]. At initial presentation and in hospitalized patients, the incidence of abnormal serum liver function tests (LFTs) varies from 22% to 67%, with levels of elevation ranging from minor to severe[12-14]. Autopsy findings from the case series also demonstrated mild microvesicular steatosis and lobular and portal inflammation[15].

To date, the findings have concentrated on evidence of hepatocellular injury as well as serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevations[16-18]. Several studies also observed that abnormal LFTs during hospitalization had been linked with disease severity[19-22]. One article that included over 2000 patients in the United States investigated ALT increases and their associations with disease severity, also emphasizing the rarity of cholestasis[20]. Despite a myriad of research on the severe COVID-19 progression, we noticed a small number of reported reports on the consequences. Previously, Faruqui *et al*[11] described a condition characterized by increases in LFTs, particularly markedly elevated serum alkaline phosphatase (ALP), and radiographic findings indicating biliary tract inflammation, primarily bile duct stricture, similar to those seen in critically ill patients with secondary sclerosing cholangitis (SSC)[23]. Still, this condition named COVID-19-associated cholangiopathy is not antecedently reviewed and discussed. This review comprehensively summarizes up-to-date reports from studies highlighting this condition and its perspective. Moreover, possible explanations for COVID-19-associated cholangiopathy are provided and discussed. We anticipate that this review could underline the importance of this condition since it appears to have significantly negative effects on patients’ recovery and may potentially result in long-term morbidities.

**SEARCH STRATEGY**

This narrative review was performed considering articles published from December 2019 to July 2022. The articles were searched electronically using several standard databases, including PubMed/Medline, Web of Science, and Reference Citation Analysis. Various search terms and Medical Subject Headings (MeSH) were used to identify potential articles: “COVID-19”, “cholestasis”, “alkaline phosphatase”, and “obstructive jaundice” (Supplementary Table 1). This minireview may only serve as a hypothesis-generation of all relevant articles existing in the literature. The extensive details of this condition may have been reviewed elsewhere. The included articles were only those that were published in English.

**COVID-19-ASSOCIATED CHOLANGIOPATHY**

COVID-19-associated cholangiopathy (COVID-C) or COVID-19 cholestasis has been proposed to describe a condition that occurs in individuals during and after severe COVID-19 infection[11]. It is characterized by elevated liver enzymes, especially substantial increases in serum ALP, and imaging-based biliary tract inflammation[11]. This condition appears to have significant negative effects on patient recovery. After other manifestations of COVID-19 have recovered, it may cause delayed morbidity[17], the necessity for a liver transplant, and death[11].

***Elevated serum ALP and serum gamma-glutamyl transferase levels***

COVID-19 is frequently linked with aberrant LFTs, despite the absence of disease-specific lesions on radiographic imaging or biopsy. Liver damage has been discovered to be a common feature of the highly deadly coronavirus-associated illness in humans[24]. Previous studies, mainly from China, have identified abnormal LFTs in infected individuals from the early stages of the recent SARS-CoV-2 pandemic[25-27]. Several systematic reviews with meta-analysis found that any abnormal LFTs were reported in 25%-47%[12-14,26]. Most abnormalities were elevated serum AST and ALT, representing hepatocellular injury[12,13]. Recent literature showed that acute hepatocellular injury during COVID-19 positively correlates with more severe COVID-19[20]. Furthermore, SARS-CoV-2 can enter the liver *via* the ACE-2 receptor proteins found on the bile duct epithelium, which theoretically results in “direct viral cholangiocyte injury”. Supporting this concept, the findings from meta-analyses reported serum ALP elevations occurring in up to 4.0%-13.7% of patients[12-14]. In addition, recent studies identified serum ALP elevation as an independent predictor of unfavorable outcomes, including intensive care unit (ICU) admission and hospital mortality[13,28]. Furthermore, Da *et al*[17] documented that COVID-19 patients with increased ALP levels (> 3 times of normal upper limit) were correlated with a higher likelihood of prolonged mechanical ventilation and death. In the same way, a study conducted in Iraq reported that most SARS-CoV-2 patients had abnormal liver enzyme activities, which might be associated with viral replication in the liver[16].

Similarly, serum gamma-glutamyl transferase (GGT) activity represents a sign of hepatobiliary damage, particularly cholestasis and biliary impact[29]. Previous meta-analyses revealed that COVID-19 patients had higher GGT levels than those without, ranging from 15.0-22.5%[12,13]. Although the ACE-2 receptor is primarily expressed in the biliary tree, the evidence showed that both abnormal serum ALP and GGT levels were lower than abnormal serum AST and ALT levels. We hypothesize that some abnormal hepatocellular enzymes may result from baseline chronic liver diseases. Furthermore, individuals with COVID-19 and concurrent advanced-stage liver disease may be more susceptible to severe liver damage than those without.

***Abnormal biliary tract imaging associated with COVID-19 infection***

Faruqui *et al*[11] reported that only 0.6% of patients with severe COVID-19 infection developed aberrant radiographic findings consistent with cholestatic liver damage. All had severe pneumonia with sepsis and required mechanical ventilation during admission. Extracorporeal membrane oxygenation was used on three of them. All patients underwent magnetic resonance cholangiopancreatography, which indicated aberrant findings such as beaded intrahepatic channels, peribiliary diffusion high signal, bile duct wall thickening and hyperenhancement, and common bile duct dilatation[11]. These cholangiopathies described in that study are comparable to SSC observed in patients following prolonged ICU stays[23]. This disease has been encountered in critically ill patients with infection, polytrauma, burns, or after major surgery[30,31]. SSC also has been described in a case report or small case series[11,30,31]. It has been defined as a cholangiopathy with radiographic characteristics similar to those observed in primary SSC and comparable to ischemic cholangiopathy reported following liver transplantation[31]. Endoscopic retrograde cholangiopancreatography or liver histology was used to diagnose several individuals who had SSC following a severe illness. Gelbmann *et al*[30] recorded endoscopic observations of biliary casts with the reduced biliary flow and eventual cholangitis, as well as verified cholangitis and hemorrhagic exudates in bile ducts from liver biopsy. All 26 patients in that research had respiratory failure and required mechanical ventilation[30]. The relationship between severe SSC patients and COVID-19 cholangiopathy highlights a potential connection between hypoxic liver damage or ischemic liver failure and cholestatic liver injury[11]. The portal vein and the hepatic arteries supply the liver parenchyma or hepatocytes. On the other hand, the intrahepatic biliary tree is nourished only by hepatic artery branches *via* the peribiliary vascular plexus. Given its dependence on only arterial supply, the biliary epithelium appears more sensitive to ischemia than hepatocytes, which get dual supply[32,33]. This is illustrated by instances of hepatic artery thrombosis, which occurs in 9% of adult liver transplant patients following arterial blood supply termination, commonly leading to biliary ischemia lesions such as necrosis with biliary leakage and ischemic strictures[34].

**POSSIBLE EXPLANATIONS FOR COVID-19-ASSOCIATED CHOLANGIOPATHY**

***Direct viral invasion***

Direct viral cholangiocyte injury is a hypothetically pathogenic mechanism of the virus leading to cholestatic liver injury since SARS-CoV-2 may enter the liver *via* the ACE-2 receptor protein found in the bile duct epithelium[35]. In liver tissues taken from four deceased donors of liver transplants, it was demonstrated that specific ACE-2 activity was expressed in 60% of cholangiocytes, compared with 3% of hepatocytes, suggesting that the virus might directly bind to specific ACE-2 receptors on cholangiocytes[36]. They discovered that ACE-2 expression in cholangiocytes is equivalent to ACE-2 expression in type II lung alveolar cells[36]. Also, subsequent reports have found that biliary epithelial cells exhibit a high level of ACE-2[35,37]. An *in vitro* investigation of human liver cells revealed that cholangiocytes might be more vulnerable to being infected with SARS-CoV-2 than other viruses[35]. Previous literature illustrated that viral particles in cholangiocytes had been found in ultrastructural and histological studies, highlighting the possibility that cholestatic damage may be caused by SARS-CoV-2 direct infection of biliary epithelial cells[11,38]. Furthermore, transmembrane protease serine 2 (TMPRSS2), the key host protease that allows several coronaviruses to enter the cells, including SARS-CoV-2, has been found to be associated with viral invasion mechanism since its activity was expressed in cholangiocytes[39]. Its actions lead to cell apoptosis, impaired transportation of bile acids, and epithelial barrier dysfunction[35]. On the other hand, another report documented that the proportion of cells expressing ACE-2 and TMPRSS2 was only 2.50% for cholangiocytes and 0.04% for hepatocytes, questioning the uncertain hypothesis of a direct viral effect on liver and bile duct cells[40].

***Ischemic injury caused by microvascular coagulopathy***

The previously discussed cholestatic injury might result from ischemic damage caused by microvascular coagulopathy and/or hypotension during critical illness or sepsis[11,19,21]. Researchers have found that SARS-CoV-2 enters the host *via* the respiratory epithelial ACE-2 receptor[41]. ACE-2 is, nevertheless, widely expressed in endothelial cells of minor and major vessels across the body[37]. The expression of ACE-2 in the vascular endothelium has been proposed as a key pathogenetic factor in the widespread coagulation that contributes considerably to COVID-19 morbidity and mortality[19,21]. A recent case series discovered many platelet-fibrin microthrombi in postmortem liver cells[36]. However, another case series of 40 COVID-19 cases found sinusoidal microthrombi in only 15%, whereas most reported macrovascular steatosis (75%) and mild lobular necroinflammation and portal inflammation (50%)[42]. These controversial issues, nonetheless, did not exclude the possibility of intravascular microthrombi and thrombosis theory. More research on this topic may be warranted.

***Drug-induced cholestatic liver injury***

Another possible explanation for COVID-C is drug-induced cholestatic liver injury. A wide range of medications has been investigated throughout this pandemic. Among these, remsidivir[43,44], lopinavir[45], ritonavir[45], and interleukin-6 antagonists (tocilizumab)[46] have been reported as a cause of increased ALT levels. However, the pattern of biliary injury from pathological examination strongly supports that this hypothesis was insufficient[43,44,46]. Besides, no single medication was constantly delivered to all patients with COVID-19 infection, resulting in inconclusive confirmation of this issue.

***Alteration of gut microbiota***

Interestingly, changes in the gut microbiota may also lead to cholestatic damage[47]. When SARS-CoV-2 infects the enterocytes, it inhibits the absorption of intestinal tryptophan, therefore resulting in the generation of antimicrobial peptides, mostly through the downregulation of ACE2 following viral entrance[48,49]. It has been proposed that disruption of the gut-liver axis may increase the likelihood of developing severe COVID-19 in patients with non-alcoholic fatty liver disease[50]. In addition, the gut microbiota has been used as a prospective target for adjuvant therapy during SARS-CoV-2 infection[51,52].

***Cytokine release syndrome***

Moreover, cytokine release syndrome (CRS), which occurs in both SSC and COVID-19, is another sign that the pathophysiology of SSC-associated severe illnesses and COVID-C may be pathogenetically similar[32]. Documents indicating that CRS can produce severe cholestatic liver damage suggest that the biliary epithelium is partially sensitive to CRS-immune mediated damage[53]. Overall, we may assume that the inducers, such as SARS-CoV-2 epithelial infection, microthrombosis, or the magnitude of the COVID-19 CRS, aggravate the severity and frequency of COVID-19 infection[11].

**CLINICAL IMPLICATION**

This review provides some important and interesting points. Recently, many researchers raised the question of when the COVID-19 pandemic will end. One statistical report showed that the COVID-19 pandemic could terminate in 2022, but COVID-19 could be one or two times more fatal than seasonal influenza by 2023[54]. Understanding the complications and consequences after COVID-19 infection would help clinicians prevent such conditions and improve the quality of care during the post-infection period. Knowledge and evidence regarding COVID-19-associated cholangiopathy are comparably low despite the growing literature on COVID-19 and other complications. This review could pave the way for a better comprehension of this condition. Future research to completely explain the behind mechanism would advance the treatment and management paradigm. Furthermore, this mini-review will help healthcare professionals recognize this disease and its circumstances better.

**CONCLUSION**

SARS-CoV-2 infection has taken our world into a disastrous situation. Severe COVID-19 patients may encounter COVID-19-associated cholangiopathy, similar to those with SSC after critical illness. COVID-19 infection initially signifies the virus's contact with ACE-2 receptors (expressed in cholangiocytes and the vascular endothelium). Based on current evidence, several theories were described in this review, including direct viral invasion, microvascular coagulopathy, alteration of the gut microbiota, drug-induced liver injury, and CRS (Figure 1). The exact underlining pathogenesis might not be concluded at this moment, raising the importance of further investigations into this issue. COVID-C may be rarely found in patients with severe COVID-19 infection but is associated with increased mortality and impaired quality of life. We anticipate that the findings described in this review will advance more translational research, resulting in a better understanding and improved treatment of COVID-C in the near future.

**REFERENCES**

1 **Wang C**, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet* 2020; **395**: 470-473 [PMID: 31986257 DOI: 10.1016/S0140-6736(20)30185-9]

2 **World Health Organization**. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. [cited September 30 2022]. Available from: https://covid19.who.int/ [DOI: 10.46945/bpj.10.1.03.01]

3 **Ong SWX**, Coleman KK, Chia PY, Thoon KC, Pada S, Venkatachalam I, Fisher D, Tan YK, Tan BH, Ng OT, Ang BSP, Leo YS, Wong MSY, Marimuthu K. Transmission modes of severe acute respiratory syndrome coronavirus 2 and implications for infection control: a review. *Singapore Med J* 2022; **63**: 61-67 [PMID: 32729311 DOI: 10.11622/smedj.2020114]

4 **Kuhn JH**, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. *Cell Mol Life Sci* 2004; **61**: 2738-2743 [PMID: 15549175 DOI: 10.1007/s00018-004-4242-5]

5 **Hoffmann M**, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020; **181**: 271-280.e8 [PMID: 32142651 DOI: 10.1016/j.cell.2020.02.052]

6 **Patel AP**, Sanders TK, Prakash P, Law J, Alvencar S, Choi A, Shah J, Patel K, Srivoleti P, Chauhan K, Weissman S, Holzwanger E, Dhingra R, Nguyen M, Kim D, Sidhu T, Stallwood C, Dickstein A, Parekh N, Altayar O, Ciorba MA, Yu J, Chen LA, Tabibian JH, Limketkai BN. Gastrointestinal Manifestations of Coronavirus Disease 2019 Across the United States: A Multicenter Cohort Study. *Gastro Hep Adv* 2022; **1**: 909-915 [PMID: 35874930 DOI: 10.1016/j.gastha.2022.07.002]

7 **Cheung KS**, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, Ng YY, Chu MY, Chung TWH, Tam AR, Yip CCY, Leung KH, Fung AY, Zhang RR, Lin Y, Cheng HM, Zhang AJX, To KKW, Chan KH, Yuen KY, Leung WK. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. *Gastroenterology* 2020; **159**: 81-95 [PMID: 32251668 DOI: 10.1053/j.gastro.2020.03.065]

8 **Bangash MN**, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. *Lancet Gastroenterol Hepatol* 2020; **5**: 529-530 [PMID: 32203680 DOI: 10.1016/S2468-1253(20)30084-4]

9 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

10 **Feng Z**, Yu Q, Yao S, Luo L, Zhou W, Mao X, Li J, Duan J, Yan Z, Yang M, Tan H, Ma M, Li T, Yi D, Mi Z, Zhao H, Jiang Y, He Z, Li H, Nie W, Liu Y, Zhao J, Luo M, Liu X, Rong P, Wang W. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. *Nat Commun* 2020; **11**: 4968 [PMID: 33009413 DOI: 10.1038/s41467-020-18786-x]

11 **Faruqui S**, Okoli FC, Olsen SK, Feldman DM, Kalia HS, Park JS, Stanca CM, Figueroa Diaz V, Yuan S, Dagher NN, Sarkar SA, Theise ND, Kim S, Shanbhogue K, Jacobson IM. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. *Am J Gastroenterol* 2021; **116**: 1414-1425 [PMID: 33993134 DOI: 10.14309/ajg.0000000000001264]

12 **Wijarnpreecha K**, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, Kim D. COVID-19 and liver injury: a meta-analysis. *Eur J Gastroenterol Hepatol* 2021; **33**: 990-995 [PMID: 32639420 DOI: 10.1097/MEG.0000000000001817]

13 **Del Zompo F**, De Siena M, Ianiro G, Gasbarrini A, Pompili M, Ponziani FR. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. *Eur Rev Med Pharmacol Sci* 2020; **24**: 13072-13088 [PMID: 33378061 DOI: 10.26355/eurrev\_202012\_24215]

14 **Wu Y**, Li H, Guo X, Yoshida EM, Mendez-Sanchez N, Levi Sandri GB, Teschke R, Romeiro FG, Shukla A, Qi X. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. *Hepatol Int* 2020; **14**: 621-637 [PMID: 32710250 DOI: 10.1007/s12072-020-10074-6]

15 **Xu Z**, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420-422 [PMID: 32085846 DOI: 10.1016/S2213-2600(20)30076-X]

16 **Hwaiz R**, Merza M, Hamad B, HamaSalih S, Mohammed M, Hama H. Evaluation of hepatic enzymes activities in COVID-19 patients. *Int Immunopharmacol* 2021; **97**: 107701 [PMID: 33930704 DOI: 10.1016/j.intimp.2021.107701]

17 **Da BL**, Suchman K, Roth N, Rizvi A, Vincent M, Trindade AJ, Bernstein D, Satapathy SK; Northwell COVID-19 Research Consortium. Cholestatic liver injury in COVID-19 is a rare and distinct entity and is associated with increased mortality. *J Intern Med* 2021; **290**: 470-472 [PMID: 33786906 DOI: 10.1111/joim.13292]

18 **Goel H**, Harmouch F, Garg K, Saraiya P, Daly T, Kumar A, Hippen JT. The liver in COVID-19: prevalence, patterns, predictors, and impact on outcomes of liver test abnormalities. *Eur J Gastroenterol Hepatol* 2021; **33**: e274-e281 [PMID: 33369962 DOI: 10.1097/MEG.0000000000002021]

19 **Ferm S**, Fisher C, Pakala T, Tong M, Shah D, Schwarzbaum D, Cooley V, Hussain S, Kim SH. Analysis of Gastrointestinal and Hepatic Manifestations of SARS-CoV-2 Infection in 892 Patients in Queens, NY. *Clin Gastroenterol Hepatol* 2020; **18**: 2378-2379.e1 [PMID: 32497637 DOI: 10.1016/j.cgh.2020.05.049]

20 **Phipps MM**, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. *Hepatology* 2020; **72**: 807-817 [PMID: 32473607 DOI: 10.1002/hep.31404]

21 **Fan Z**, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol* 2020; **18**: 1561-1566 [PMID: 32283325 DOI: 10.1016/j.cgh.2020.04.002]

22 **Hundt MA**, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. *Hepatology* 2020; **72**: 1169-1176 [PMID: 32725890 DOI: 10.1002/hep.31487]

23 **Laurent L**, Lemaitre C, Minello A, Plessier A, Lamblin G, Poujol-Robert A, Gervais-Hasenknopf A, Pariente EA, Belenotti P, Mostefa-Kara N, Sogni P, Legrand M, Cournac JM, Tamion F, Savoye G, Bedossa P, Valla DC, Vilgrain V, Goria O. Cholangiopathy in critically ill patients surviving beyond the intensive care period: a multicentre survey in liver units. *Aliment Pharmacol Ther* 2017; **46**: 1070-1076 [PMID: 29023905 DOI: 10.1111/apt.14367]

24 **Xu L**, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int* 2020; **40**: 998-1004 [PMID: 32170806 DOI: 10.1111/Liv.14435]

25 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

26 **Mao R**, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; **5**: 667-678 [PMID: 32405603 DOI: 10.1016/S2468-1253(20)30126-6]

27 **Wu J**, Liu J, Zhao X, Liu C, Wang W, Wang D, Xu W, Zhang C, Yu J, Jiang B, Cao H, Li L. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. *Clin Infect Dis* 2020; **71**: 706-712 [PMID: 32109279 DOI: 10.1093/cid/ciaa199]

28 **Aghemo A**, Piovani D, Parigi TL, Brunetta E, Pugliese N, Vespa E, Omodei PD, Preatoni P, Lleo A, Repici A, Voza A, Cecconi M, Malesci A, Bonovas S, Danese S; Humanitas COVID-19 Task Force. COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. *Clin Gastroenterol Hepatol* 2020; **18**: 2366-2368.e3 [PMID: 32437870 DOI: 10.1016/j.cgh.2020.05.011]

29 **Chand K**, Thakur S. "Significance of serum gamma glutamyl transpeptidase in cholestatic jaundice". *Indian J Med Sci* 1997; **51**: 270-274 [PMID: 9491680]

30 **Gelbmann CM**, Rümmele P, Wimmer M, Hofstädter F, Göhlmann B, Endlicher E, Kullmann F, Langgartner J, Schölmerich J. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. *Am J Gastroenterol* 2007; **102**: 1221-1229 [PMID: 17531010 DOI: 10.1111/j.1572-0241.2007.01118.x]

31 **Lin T**, Qu K, Xu X, Tian M, Gao J, Zhang C, Di Y, Zhang Y, Liu C. Sclerosing cholangitis in critically ill patients: an important and easily ignored problem based on a German experience. *Front Med* 2014; **8**: 118-126 [PMID: 24415157 DOI: 10.1007/s11684-014-0306-6]

32 **Leonhardt S**, Veltzke-Schlieker W, Adler A, Schott E, Hetzer R, Schaffartzik W, Tryba M, Neuhaus P, Seehofer D. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. *Crit Care* 2015; **19**: 131 [PMID: 25886728 DOI: 10.1186/s13054-015-0861-5]

33 **Gudnason HO**, Björnsson ES. Secondary sclerosing cholangitis in critically ill patients: current perspectives. *Clin Exp Gastroenterol* 2017; **10**: 105-111 [PMID: 28694703 DOI: 10.2147/CEG.S115518]

34 **Mourad MM**, Liossis C, Gunson BK, Mergental H, Isaac J, Muiesan P, Mirza DF, Perera MT, Bramhall SR. Etiology and management of hepatic artery thrombosis after adult liver transplantation. *Liver Transpl* 2014; **20**: 713-723 [PMID: 24652787 DOI: 10.1002/Lt.23874]

35 **Zhao B**, Ni C, Gao R, Wang Y, Yang L, Wei J, Lv T, Liang J, Zhang Q, Xu W, Xie Y, Wang X, Yuan Z, Liang J, Zhang R, Lin X. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. *Protein Cell* 2020; **11**: 771-775 [PMID: 32303993 DOI: 10.1007/s13238-020-00718-6]

36 **Chai X,** Hu L, Zhang Y, Han W, Lu Z, Ke A, Zhou J, Shi G, Fang N, Fan J, Cai J, Fan J, Lan F. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv (e-pub ahead of print 1 January 2020; DOI:10.1101/2020.02.03.931766). [DOI:10.1101/2020.02.03.931766]

37 **Hamming I**, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004; **203**: 631-637 [PMID: 15141377 DOI: 10.1002/path.1570]

38 **Wang Y**, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. *J Hepatol* 2020; **73**: 807-816 [PMID: 32437830 DOI: 10.1016/j.jhep.2020.05.002]

39 **Schönfelder K**, Breuckmann K, Elsner C, Dittmer U, Fistera D, Herbstreit F, Risse J, Schmidt K, Sutharsan S, Taube C, Jöckel KH, Siffert W, Kribben A, Möhlendick B. *Transmembrane serine protease 2* Polymorphisms and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection: A German Case-Control Study. *Front Genet* 2021; **12**: 667231 [PMID: 33968142 DOI: 10.3389/fgene.2021.667231]

40 **De Smet V**, Verhulst S, van Grunsven LA. Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2. *J Hepatol* 2020; **73**: 993-995 [PMID: 32473193 DOI: 10.1016/j.jhep.2020.05.030]

41 **Zamorano Cuervo N**, Grandvaux N. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. *Elife* 2020; **9** [PMID: 33164751 DOI: 10.7554/eLife.61390]

42 **Lagana SM**, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, Del Portillo A, De Michele S, de Gonzalez AK, Saqi A, Khairallah P, Chong AM, Park H, Uhlemann AC, Lefkowitch JH, Verna EC. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. *Mod Pathol* 2020; **33**: 2147-2155 [PMID: 32792598 DOI: 10.1038/s41379-020-00649-x]

43 **Beigel JH**, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020; **383**: 1813-1826 [PMID: 32445440 DOI: 10.1056/NEJMoa2007764]

44 **Wang Y**, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; **395**: 1569-1578 [PMID: 32423584 DOI: 10.1016/S0140-6736(20)31022-9]

45 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.**; Clinical Practice Guideline Panel: Chair:; Panel members; EASL Governing Board representative:. EASL Clinical Practice Guidelines: Drug-induced liver injury. *J Hepatol* 2019; **70**: 1222-1261 [PMID: 30926241 DOI: 10.1016/j.jhep.2019.02.014]

46 **Guaraldi G**, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, Santoro A, Di Gaetano M, Puzzolante C, Carli F, Bedini A, Corradi L, Fantini R, Castaniere I, Tabbì L, Girardis M, Tedeschi S, Giannella M, Bartoletti M, Pascale R, Dolci G, Brugioni L, Pietrangelo A, Cossarizza A, Pea F, Clini E, Salvarani C, Massari M, Viale PL, Mussini C. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol* 2020; **2**: e474-e484 [PMID: 32835257 DOI: 10.1016/S2665-9913(20)30173-9]

47 **Zuo T**, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS, Ng SC. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. *Gastroenterology* 2020; **159**: 944-955.e8 [PMID: 32442562 DOI: 10.1053/j.gastro.2020.05.048]

48 **Hashimoto T**, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, Sigl V, Hanada T, Hanada R, Lipinski S, Wild B, Camargo SM, Singer D, Richter A, Kuba K, Fukamizu A, Schreiber S, Clevers H, Verrey F, Rosenstiel P, Penninger JM. ACE2 Links amino acid malnutrition to microbial ecology and intestinal inflammation. *Nature* 2012; **487**: 477-481 [PMID: 22837003 DOI: 10.1038/nature11228]

49 **Liévin-Le Moal V**, Servin AL. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. *Clin Microbiol Rev* 2006; **19**: 315-337 [PMID: 16614252 DOI: 10.1128/CMR.19.2.315-337.2006]

50 **Assante G**, Williams R, Youngson NA. Is the increased risk for MAFLD patients to develop severe COVID-19 Linked to perturbation of the gut-liver axis? *J Hepatol* 2021; **74**: 487-488 [PMID: 32574578 DOI: 10.1016/j.jhep.2020.05.051]

51 **Gasbarrini G**, Dionisi T, Franceschi F, Gasbarrini A. Editorial - COVID-19 and the microbiota: new kids on the block. *Eur Rev Med Pharmacol Sci* 2020; **24**: 5189-5191 [PMID: 32432790 DOI: 10.26355/eurrev\_202005\_21218]

52 **Di Renzo L**, Merra G, Esposito E, De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? *Eur Rev Med Pharmacol Sci* 2020; **24**: 4062-4063 [PMID: 32374010 DOI: 10.26355/eurrev\_202004\_20977]

53 **Abdalian R**, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. *Hepatology* 2006; **44**: 1063-1074 [PMID: 17058222 DOI: 10.1002/hep.21405]

54 **Chen JM**. Novel statistics predict the COVID-19 pandemic could terminate in 2022. *J Med Virol* 2022; **94**: 2845-2848 [PMID: 35150458 DOI: 10.1002/jmv.27661]

**Footnotes**

**Conflict-of-interest statement:** The author declares that he has no competing interests to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 9, 2022

**First decision:** August 29, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Thailand

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Laranjeira C, Portugal; Yu MC, Taiwan **S-Editor:** Chen YL **L-Editor:** Wang TQ **P-Editor:** Chen YL

**Figure Legends**



**Figure 1 Possible mechanisms involved in the pathogenesis of COVID-19-associated cholangiopathy during and after COVID-19 infection.** ACE-2: Angiotensin-converting enzyme 2; COVID-19: 2019 coronavirus disease; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; TMPRSS2: Transmembrane protease serine 2.